Natural Products for Antithrombosis

Cen Chen1, Feng-Qing Yang1, Qian Zhang1

  • 1School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, China.

Insights

Natural products show promise in preventing and treating thrombosis, a condition linked to major diseases. This review details thrombus formation mechanisms and natural antithrombotic strategies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Pathophysiology

Background:

  • Thrombosis is a critical factor in diseases like atherosclerosis, heart disease, and stroke.
  • Understanding thrombus formation at molecular and cellular levels is key for effective treatment.
  • Natural products offer potential therapeutic benefits for thrombotic disorders.

Purpose of the Study:

  • To elucidate the mechanisms of thrombus formation.
  • To review natural products with antithrombotic properties.
  • To categorize natural antithrombotic agents based on their mechanisms.

Main Methods:

  • Review of scientific literature on thrombosis.
  • Analysis of thrombus formation pathways (coagulation, platelet activation, blood flow).
  • Categorization of natural products by antithrombotic action (anticoagulation, antiplatelet, fibrinolysis).

Main Results:

  • Thrombus formation involves complex interactions within the coagulation system, platelet dynamics, and hemodynamics.
  • Numerous natural products exhibit anticoagulant, antiplatelet aggregation, and fibrinolytic activities.
  • Specific bioactive components from natural sources demonstrate significant antithrombotic potential.

Conclusions:

  • Natural products represent a promising avenue for antithrombotic therapies.
  • Targeting coagulation, platelet function, and fibrinolysis with natural agents can mitigate thrombotic risks.
  • Further research into natural product-based antithrombotics is warranted for clinical application.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
469
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
391
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
593